New hope for kids with rare blood disorder: revolade trial launches
NCT ID NCT06287268
First seen Feb 21, 2026 · Last updated May 11, 2026 · Updated 14 times
Summary
This study looks at the safety and effectiveness of the drug Revolade (eltrombopag) in children aged 6 to 17 with aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. The children in this study have not received a standard treatment called anti-thymocyte globulin (ATG). Researchers will track serious side effects and other reactions to see how well the drug works when used alongside ATG.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGNagoya, Aichi-ken, 453-8511, Japan
-
Novartis Investigative Site
RECRUITINGNagoya, Aichi-ken, 4668560, Japan
-
Novartis Investigative Site
RECRUITINGToyoake, Aichi-ken, 4701192, Japan
-
Novartis Investigative Site
RECRUITINGChiba, Chiba, 260 8677, Japan
-
Novartis Investigative Site
RECRUITINGAmagasaki, Hyōgo, 660 8550, Japan
-
Novartis Investigative Site
RECRUITINGKobe, Hyōgo, 6500047, Japan
-
Novartis Investigative Site
RECRUITINGMatsumoto, Nagano, 3908621, Japan
-
Novartis Investigative Site
RECRUITINGShimajiri-Gun, Okinawa, 901-1303, Japan
-
Novartis Investigative Site
RECRUITINGIzumi, Osaka, 5941101, Japan
-
Novartis Investigative Site
RECRUITINGOsaka, Osaka, 5340021, Japan
-
Novartis Investigative Site
RECRUITINGSakai, Osaka, 590-0197, Japan
-
Novartis Investigative Site
RECRUITINGSaitama, Saitama, 3308777, Japan
-
Novartis Investigative Site
RECRUITINGOhtsu, Shiga, 5202192, Japan
-
Novartis Investigative Site
RECRUITINGChuo Ku, Tokyo, 1048560, Japan
-
Novartis Investigative Site
RECRUITINGŌta-ku, Tokyo, 143 8541, Japan
-
Novartis Investigative Site
RECRUITINGSetagaya-ku, Tokyo, 1578535, Japan
-
Novartis Investigative Site
RECRUITINGWakayama, Wakayama, 641-8510, Japan
Conditions
Explore the condition pages connected to this study.